Literature DB >> 20074466

Exhaled nitric oxide and nitric oxide synthase expression in Hodgkin's disease.

G Guida1, B Culla, T Scirelli, G Bellone, S Sciascia, L Brussino, D Novero, G Palestro, E Heffler, P Gavarotti, G Rolla, C Bucca.   

Abstract

Hodgkin's disease (HD) is a malignant lymphoma with frequent mediastinal involvement, characterized by a significant inflammatory infiltration. Exhaled nitric oxide (FENO), is present in healthy humans, and has been proven to be increased in eosinophilic diseases such as allergic asthma. We investigated whether FENO is increased in mediastinal HD and whether NO is produced by lymphoma tissue. To this aim FENO was measured in 56 HD patients, 17 with and 39 without bulky mediastinal involvement, in the period from January 2007 to December 2008. Thirty-seven patients were reassessed after remission. Lymph node biopsies of 10 patients were evaluated for inducible (iNOS) and constitutive (eNOS) nitric oxide synthase expression by immunohistochemistry. FENO resulted significantly related to the mediastinal mass maximum diameter (p=0.009) and was significantly higher in patients with as compared to those without bulky mediastinal disease (38.7 ppb, CI 95% 19.3-58.0, versus 20.7 ppb, CI 95% 16.6-24.7; p=0.009). iNOS and eNOS immunoreactivity was observed in tumour and inflammatory cells (eosinophils and histiocytes). Only in patients with bulky mediastinal HD there was a significant decrease in FENO (from 50.4 ppb CI 95% 18.0-82.8 to 11.1 ppb CI 95% 4.4-17.8, p=0.011). In conclusion, high FENO and NOS expression in lymph-nodes indicate that NO is a component of the inflammatory network of HD. FENO may be proposed for the assessment and follow up of bulky mediastinal HD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20074466     DOI: 10.1177/039463200902200418

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis.

Authors:  John Leung; Ann Nguyen-Traxler; Erika M Lee; Jason S Yip; Joel V Weinstock; Walter W Chan; Peter Ngo; Barbara J Weinstein; Peter A Bonis
Journal:  Allergy Asthma Proc       Date:  2012 Nov-Dec       Impact factor: 2.587

2.  Quantitative detection of nitric oxide in exhaled human breath by extractive electrospray ionization mass spectrometry.

Authors:  Susu Pan; Yong Tian; Ming Li; Jiuyan Zhao; Lanlan Zhu; Wei Zhang; Haiwei Gu; Haidong Wang; Jianbo Shi; Xiang Fang; Penghui Li; Huanwen Chen
Journal:  Sci Rep       Date:  2015-03-04       Impact factor: 4.379

3.  Measurement of exhaled nitric oxide and serum surfactant protein D levels for monitoring radiation pneumonitis following thoracic radiotherapy.

Authors:  Hideya Yamazaki; Norihiro Aibe; Satoaki Nakamura; Naomi Sasaki; Gen Suzuki; Ken Yoshida; Kei Yamada; Masahiko Koizumi; Taichiro Arimoto; Yoshinobu Iwasaki; Yoshiko Kaneko; Koichi Takayama
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

4.  Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients?

Authors:  Irina Enache; Georges Noel; M Young Jeung; Nicolas Meyer; Monique Oswald-Mammosser; Emile Urban-Kraemer; Catherine Schumacher; Bernard Geny; Elisabeth Quoix; Anne Charloux
Journal:  Radiat Oncol       Date:  2012-07-28       Impact factor: 3.481

Review 5.  Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy.

Authors:  Pierachille Santus; Maurizio Rizzi; Dejan Radovanovic; Andrea Airoldi; Andrea Cristiano; Rosalynn Conic; Stephen Petrou; Paolo Daniele Maria Pigatto; Nicola Bragazzi; Delia Colombo; Mohamad Goldust; Giovanni Damiani
Journal:  Biomed Res Int       Date:  2018-09-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.